Frontiers in Oncology (Sep 2023)

Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM)

  • Xiaobing Yang,
  • Xiaobing Yang,
  • Di Lu,
  • Di Lu,
  • Yanfei Sun,
  • Yanfei Sun,
  • Tiandi Wei,
  • Dulegeqi Man,
  • Anbin Chen,
  • Tao Luo,
  • Tao Luo,
  • Feihu Zhao,
  • Feihu Zhao,
  • Xuemeng Liu,
  • Xuemeng Liu,
  • Bo Cheng,
  • Bo Cheng,
  • Xu Wang,
  • Xu Wang,
  • Peng Zhao,
  • Peng Zhao,
  • Donghai Wang,
  • Donghai Wang,
  • Xingang Li,
  • Xingang Li

DOI
https://doi.org/10.3389/fonc.2023.1255164
Journal volume & issue
Vol. 13

Abstract

Read online

IntroductionSafranal is an active component of the traditional Tibetan medicine (TTM) saffron, which has potential anticancer activity.Methods and resultsHere, we studied the therapeutic effect and mechanism of safranal on GBM. CCK-8, GBM-brain organoid coculture experiments and 3D tumour spheroid invasion assays showed that safranal inhibited GBM cell proliferation and invasion in vitro. Network pharmacology, RNA-seq, molecular docking analysis, western blotting, apoptosis, and cell cycle assays predicted and verified that safranal could promote GBM cell apoptosis and G2/M phase arrest and inhibit the PI3K/AKT/mTOR axis. In vivo experiments showed that safranal could inhibit GBM cell growth alone and in combination with TMZ.ConclusionThis study revealed that safranal inhibits GBM cell growth in vivo and in vitro, promotes GBM cell apoptosis and G2/M phase arrest, inhibits the PI3K/AKT/mTOR axis and cooperate with TMZ.

Keywords